You're crazy throwing out B numbers, lol!! I feel the same anytime I am thinking about stating such large numbers in public and then look at its share price and market cap. I'm sure anyone who isn't familiar with leronlimab's success thus far would definitely think I'm crazy or delusional (and even some that are familiar with it) if/when I mention its market potential.
I share your confidence in cancer being successful and am fortunate enough to be able to continue to add shares / average down while we are in the low-to-mid $.40s (had a little over 40,000 share limit order fill today actually). Every time I run the numbers (for US only), I scratch my head of what I am missing....but have yet to find anything to make me concerned about the future of CYDY. Sure the finances are ugly, but IMO there is little doubt leronlimab will make it to market for combo (worst case scenario) and even with further dilution and licensed at decent royalty it is worth multiples of where we are currently trading.....add in mono, PCa, GvHD, cancer or any other indication and/or going some of these alone the market grows exponentially. As long as leronlimab proves successful in trials, I'm adding shares as my budget, risk tolerance and wife allow.
As ohm mentioned on ihub.....and I share these thoughts: " What I look for in doing DD is scientific results, potential market, nearness to market and finances. Which gives you a good idea of risk/reward. In biopharma any of these can trip you up badly. But the reward when successful beats regular stocks by far. CYDY is great with all of my criteria except finances. When doing my DD I figured in dilution rather than any assets sales in assessing risk/reward and it still came out positive."
BTW, welcome to the board ohm20 and great post! It is always great to have another respectable and value-added poster.....I say that even if you are not bullish/as bullish as myself or some of us.
I've been MIA for a little over a week, but have been trying to keep up with the MBs and pressured share price. Our family grew by one last week (boy), so my time and efforts have been focused elsewhere. I didn't have time to add anything beneficial and am doing my best from downgrading to "I agree" type posts (although this post pretty much is that). lol
Even with delays and current share price, I believe 2019 will end nicely for all current shareholders and only looks brighter in 2020 and the out years! Time will tell!
I share your confidence in cancer being successful and am fortunate enough to be able to continue to add shares / average down while we are in the low-to-mid $.40s (had a little over 40,000 share limit order fill today actually). Every time I run the numbers (for US only), I scratch my head of what I am missing....but have yet to find anything to make me concerned about the future of CYDY. Sure the finances are ugly, but IMO there is little doubt leronlimab will make it to market for combo (worst case scenario) and even with further dilution and licensed at decent royalty it is worth multiples of where we are currently trading.....add in mono, PCa, GvHD, cancer or any other indication and/or going some of these alone the market grows exponentially. As long as leronlimab proves successful in trials, I'm adding shares as my budget, risk tolerance and wife allow.
As ohm mentioned on ihub.....and I share these thoughts: " What I look for in doing DD is scientific results, potential market, nearness to market and finances. Which gives you a good idea of risk/reward. In biopharma any of these can trip you up badly. But the reward when successful beats regular stocks by far. CYDY is great with all of my criteria except finances. When doing my DD I figured in dilution rather than any assets sales in assessing risk/reward and it still came out positive."
BTW, welcome to the board ohm20 and great post! It is always great to have another respectable and value-added poster.....I say that even if you are not bullish/as bullish as myself or some of us.
I've been MIA for a little over a week, but have been trying to keep up with the MBs and pressured share price. Our family grew by one last week (boy), so my time and efforts have been focused elsewhere. I didn't have time to add anything beneficial and am doing my best from downgrading to "I agree" type posts (although this post pretty much is that). lol
Even with delays and current share price, I believe 2019 will end nicely for all current shareholders and only looks brighter in 2020 and the out years! Time will tell!
